Article Figures & Data
Figures
- Figure 1.
Clinical categorization of anti-topo I antibody-positive patients and their relative autoantibody titers. Anti-topo I antibody concentrations were significantly elevated in patients fulfilling the 2013 SSc criteria (panel A) compared to those who did not meet these requirements (panel B) — lung disease (bronchiectasis, empyema, tuberculosis, and usual interstitial pneumonia) and other immune-mediated conditions (Sjögren syndrome, Graves’ disease, inflammatory bowel disease, and sarcoid; p = 0002). Anti-topo I antibody: antitopoisomerase I antibody; SSc: systemic sclerosis.
- Figure 2.
Anti-topo I antibody levels may be useful in predicting risk for SSc. Using logistic regression, an estimated probability of 1 for SSc was attained at anti-Scl-70 antibody level of about 125 AU/ml. Anti-topo I antibody: antitopoisomerase I antibody; SSc: systemic sclerosis.
In this issue
